Trading & Business Update

About this update from Cambridge Nutritional Sciences Plc

Cambridge Nutritional Sciences plc   (the "Company" or "CNSL" )   Trading & Business Update   Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, is pleased to announce an update on the Company's trading for the year ended 31 March 2026, ahead of the release of its audited final results in July 2026.   Highlights:   ·      Total Revenue expected to be £7.0m (2025: £8.3m) ·      Gross profit margin of 67.8% (2025: 65.3%) ·      Adjusted EBITDA** expected to show loss of £0.4m (2025: profit of £0.4m) ·      Net cash balance of £2.6m (2025: £4.9m) **Adjusted for exceptional items and share based payment charges   2026 financial performance:   Revenue was in line with market expectations after adjusting for reduced and delayed orders from the Middle East & Asia in the second half of the year. These were driven by a challenging and disrupted trading environment created by geopolitical instability and uncertainty, rather than a loss of local business partners. After adjusting for the impacted regions for the full year, underlying year on year revenue growth was approximately 11%.   Despite these revenue challenges, a continued focus on efficiencies and cost control across the business has resulted in a strong gross margin of 67.8% as well as an EBITDA loss of only £0.4m (vs £0.4m profit in 2025).   James Cooper, CEO, commented:   "I am pleased that underlying revenue adjusting for the economic disruption showed 11% growth; driven in particular by the UK and Indian markets, however we remain mindful of the potential for ongoing global uncertainties.   We continue to drive manufacturing efficiencies and are pleased to report a gross margin increase to 67.8%. This is a testament to all the hard work of my colleagues.   We are continuing to successfully progress our IVDR development programme following our heavy investment in capital equipment this year, which we believe will deliver significant product, cost and market position advantages to the Company for years to come.   I look forward to updating the market further at our results in July 2026."   The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014     Contacts:    Cambridge Nutritional Sciences plc         www.cnsplc.com Carolyn Rand, Non-Executive Chair [email protected] James Cooper, Chief Executive Officer Ajay Patel, Chief Financial Officer   Cavendish Capital Markets Limited        Tel: 020 7220 0500 Geoff Nash / Edward Whiley / (Corporate Finance) Nigel Birks / Harriet Ward (ECM) About Cambridge Nutritional Sciences plc Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.  

View stock analysis, news, and events for Cambridge Nutritional Sciences Plc